Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silo Pharma (SILO) Common Equity (2019 - 2025)

Silo Pharma's Common Equity history spans 7 years, with the latest figure at $5.0 million for Q3 2025.

  • For Q3 2025, Common Equity fell 26.15% year-over-year to $5.0 million; the TTM value through Sep 2025 reached $5.0 million, down 26.15%, while the annual FY2024 figure was $5.0 million, 18.5% down from the prior year.
  • Common Equity for Q3 2025 was $5.0 million at Silo Pharma, up from $4.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $11.9 million in Q3 2022 and bottomed at $3.8 million in Q2 2021.
  • The 5-year median for Common Equity is $6.8 million (2024), against an average of $7.1 million.
  • The largest annual shift saw Common Equity soared 1715.1% in 2021 before it crashed 43.96% in 2024.
  • A 5-year view of Common Equity shows it stood at $9.1 million in 2021, then rose by 14.11% to $10.3 million in 2022, then crashed by 40.27% to $6.2 million in 2023, then fell by 18.5% to $5.0 million in 2024, then dropped by 0.51% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for SILO's Common Equity are $5.0 million (Q3 2025), $4.9 million (Q2 2025), and $4.0 million (Q1 2025).